https://www.selleckchem.com/products/cepharanthine.html 07-3.02, P = 1.028), IPLC characteristics of squamous cell carcinoma vs. adenocarcinoma (HR = 1.89, 95% CI 1.17-3.04, P = 0.009), clinical stage II vs. stage I (HR = 2.60, 95% CI 1.08-6.27, P = 0.033), and T2 stage vs. T1 stage (HR = 1.68, 95% CI 1.04-2.72, P = 0.034) indicated worse survival. SPLC patients demonstrated a five-year survival rate of 68.6% and a five-year RMST of 49.4 months. The choice of surgical procedure (wedge resection, segmentectomy and lobectomy) for both IPLC and SPLC had no significant effect on prognosis (P > 0.05). Patients that received radiotherapy for SPLC also demonstrated similar survival when compared with those that underwent surgery (P > 0.05). Radiotherapy and sublobar resection can be considered reasonable alternative treatments for SPLC, especially when patients are unable to tolerate lobectomy. Radiotherapy and sublobar resection can be considered reasonable alternative treatments for SPLC, especially when patients are unable to tolerate lobectomy.Strong metal-support interactions (SMSI) could improve the performance of nanoparticle catalysts through the electronic and geometric modulation of the reducible metal oxide supports. Here, SMSI is demonstrated to occur for catalysts with non-oxide carrier, such as NbOPO4 -supported Rh nanoparticles, under reduction treatment at low temperature. During CO2 hydrogenation, this Rh/NbOPO4 catalyst with SMSI exhibits impressive CO selectivity at high CO2 conversion in a wide temperature range with hindered methanation. For example, over 98.9 % CO selectivity was obtained with 39.9 % CO2 conversion at 500 °C. Mechanism investigations demonstrate that the SMSI results in the formation of a metal-support interface with weaker CO adsorption than the metallic Rh sites, thus accelerating the CO desorption, which hinders deep hydrogenation. Rh nanoparticles with small diameter of about 1.1 nm is sinter-resistant with unchanged performance d